HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Relationship between red cell mean corpuscular volume and 6-thioguanine nucleotides in patients treated with azathioprine.

Abstract
Azathioprine (AZA) is characterized by high interindividual differences in bioavailability and metabolization. The aim of the present study was to analyze, in patients treated with AZA for various immune system disorders, whether the variation in red blood cell mean corpuscular volume (deltaMCV) could be used as an indirect estimation of the level of the active immune modifier metabolite 6-thioguanine nucleotides (6-TGN). In 43 consecutive patients treated with a stable dose of AZA for at least 6 months who were not initially anemic, the erythrocyte 6-TGN levels with routine hematologic parameters were determined two to four times at 1-month intervals. In most patients MCV significantly increased after 3 months of therapy and stabilized after 6 months. The correlation between the daily dose of AZA and the 6-TGN level was mild (r = 0.51; P<.001). A weak correlation was also found between the dose of AZA and the deltaMCV after at least 6 months of therapy (r = 0.36; P<.05). The correlation between deltaMCV and 6-TGN level, however, was much better (r = 0.74; P<.001). The lack of a significant increase in MCV after 3 to 4 months of AZA therapy reflects low 6-TGN levels, sometimes a result of undertreatment. A determination of the 6-TGN level during the first months after AZA therapy is begun will allow more accurate adaptation of the effective dose. We observed that deltaMCV could be used as an indicator of 6-TGN levels after 6 months of AZA treatment. An increase in MCV of at least 6 fL is expected to reflect a 6-TGN level of about 175 pmol/8x10(8) red blood cells (probably being within a therapeutic value).
AuthorsG Decaux, F Prospert, Y Horsmans, J P Desager
JournalThe Journal of laboratory and clinical medicine (J Lab Clin Med) Vol. 135 Issue 3 Pg. 256-62 (Mar 2000) ISSN: 0022-2143 [Print] United States
PMID10711864 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Guanine Nucleotides
  • Immunosuppressive Agents
  • Thionucleotides
  • Azathioprine
Topics
  • Adult
  • Azathioprine (blood, pharmacokinetics, therapeutic use)
  • Biological Availability
  • Churg-Strauss Syndrome (blood, drug therapy)
  • Erythrocyte Indices
  • Erythrocytes (drug effects, metabolism, pathology)
  • Female
  • Guanine Nucleotides (blood)
  • Humans
  • Immune System Diseases (blood, drug therapy)
  • Immunosuppressive Agents (blood, pharmacokinetics, therapeutic use)
  • Lupus Erythematosus, Systemic (blood, drug therapy)
  • Male
  • Middle Aged
  • Still's Disease, Adult-Onset (blood, drug therapy)
  • Thionucleotides (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: